Inmed pharmaceuticals announces favorable behavioral outcomes with inm-901 in long-term preclinical alzheimer's disease study, confirming previous short-term pilot study data

Results confirm improvements in cognitive function, memory and locomotor activity achieved statistical significance in certain behavioral assessments additional molecular analyses ongoing to elucidate inm-901 mechanisms of action vancouver, british columbia--(newsfile corp. - july 30, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical alzheimer's disease ("ad") study of inm-901 which confirms previously reported findings from a short-term (3 months of dosing) pilot study, as disclosed in the company's prior press release dated april 4, 2024. similar to the short-term pilot study, this long-term dosing study was conducted using the 5xfad amyloidosis model with extended dosing duration and increased sample size as compared to the short-term study.
INM Ratings Summary
INM Quant Ranking